Case Study - Early Parkinson’s Disease

Key Takeaways

BBK Worldwide was hired to support the TEMPO trials, a combination of three phase 3 studies and an open-label extension, examining the effects of an investigational drug (tavapadon) in patients with early-onset and late-stage Parkinson’s disease.

The studies were seeking to enroll 1,200 individuals, aged 40 to 80 years.

BBK’s patient recruitment campaign for the TEMPO was selected as a finalist for the Pharmaceutical Executive APEX Awards.

Solutions

BBK’s efforts focused on general Parkinson’s disease awareness to drive interested and potentially eligible patients to sites for further screening and assessment.

Patient-facing materials included a mix of program-level materials (used across all protocols), as well as protocol-specific materials (tailored to include study-specific information).

BBK prioritized the development of a website to inform and prescreen individuals recently diagnosed with Parkinson’s disease.

The website had a sympathetic tone with the understanding that patients recently diagnosed were looking to make the most of their time and quality of life in the face of this progressive disease. The campaign tagline — Keeping Time with Parkinson’s Research — reinforced this concept.

879 The campaign drove 879 more referrals than initially projected.
1,639 BBK generated a total of 1,639 qualified referrals for the study, helping the sponsor achieve the enrollment goal of 1,200 patients.